Sp426
GUT BACTERIA DRIVEN CHEMICAL TRANSFORMATION OF DRUGS
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
In this session, you will learn about the advances in microbial biotransformation of drugs and this can impact clinical outcomes and adverse events.
In this session, you will learn about the advances in microbial biotransformation of drugs and this can impact clinical outcomes and adverse events.
Presenter
Rush University Medical Center
Tracks
Related Products
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
INTESTINAL MICROBIAL DYSBIOSIS AND IMPAIRED SCFA PRODUCTION, GLP-1 SECRETION, AND INTESTINAL BARRIER FUNCTION IN PARKINSON’S DISEASE
BACKGROUND: Diet is known to alter the risk of depression. Increasing data also demonstrate a causal role of the gut microbiome in mental illness, via the gut-brain axis. However, it remains unclear how diet and the microbiome mechanistically influence depression risk in humans…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…